How Much Weight Have People Lost on Zepbound?

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound, the brand-name version of tirzepatide, has generated substantial clinical interest since its FDA approval for chronic weight management. In pivotal trials, participants treated with tirzepatide achieved average weight losses of 15-22% of starting body weight—substantially higher than older weight-loss medications. PlexusDx provides access to compounded tirzepatide from licensed 503A pharmacies, allowing patients nationwide to explore this dual-action therapy without insurance requirements.

Clinical Trial Weight Loss Results on Tirzepatide

The SURMOUNT trial series tracked tirzepatide's effectiveness across multiple dosage strengths over 68 weeks of treatment. Participants receiving the highest maintenance dose lost approximately 22% of baseline body weight, while those on lower doses experienced 15-18% reductions. These results represent a meaningful advance compared to GLP-1 only medications, which typically produce 10-15% weight loss in similar timeframes.

Real-world data from clinical practices confirms trial outcomes hold across diverse patient populations. Individuals with type 2 diabetes, metabolic dysfunction, and varying baseline weights have demonstrated comparable weight loss trajectories to research settings. The consistency of results suggests tirzepatide's dual GLP-1 and GIP receptor mechanism addresses appetite and metabolic pathways effectively in broad patient groups.

Why Tirzepatide Produces Greater Weight Loss Than GLP-1 Alone

Tirzepatide targets two hormone pathways simultaneously: GLP-1 receptors that reduce hunger and slow stomach emptying, and GIP receptors that regulate blood glucose and energy metabolism. This dual activation appears to create a synergistic effect on weight reduction that single-pathway medications cannot match. When compared head-to-head in trials, tirzepatide consistently outperformed semaglutide, the leading GLP-1 monotherapy option.

The medication's mechanism also influences how the body processes and stores energy. By engaging both satiety centers in the brain and peripheral metabolic regulation, tirzepatide users report sustained appetite suppression and reduced cravings throughout each dosing interval. This dual action may explain why weight loss on tirzepatide continues beyond what patients experience on GLP-1 only treatments.

Individual Weight Loss Variation: Genetics and Personalization

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Understanding your genetic predisposition allows PlexusDx to recommend the therapy most likely to work for your unique physiology. Some patients may achieve optimal results with tirzepatide injection, while others might benefit from combination approaches like GLP-Squared (semaglutide plus tirzepatide) or oral formulations. This personalized approach removes guesswork and helps maximize weight loss outcomes from day one.

Cost and Access: Tirzepatide Treatment at PlexusDx

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) across all dosage levels—your dose may need to go up, but your price won't. This flat-rate pricing model eliminates the financial uncertainty of traditional dose escalation protocols, making it easier to budget for treatment. Patients nationwide can access tirzepatide without insurance, and the therapy qualifies for HSA and FSA accounts.

All PlexusDx medications come from licensed 503A compounding pharmacies that meet strict pharmaceutical standards. Treatment begins with a personalized consultation to review your medical history, weight loss goals, and genetic testing results (available through the Precision Peptide Genetic Test add-on for $298). From prescription to delivery, PlexusDx handles the logistics so you can focus on achieving meaningful weight loss results.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose on Zepbound or tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to Zepbound or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is tirzepatide more effective than semaglutide for weight loss?

Yes—head-to-head trials demonstrate tirzepatide produces greater weight loss than semaglutide alone, with average differences of 3-5% additional body weight reduction. Tirzepatide's dual GLP-1 and GIP receptor activation creates a synergistic effect that semaglutide's single-pathway mechanism cannot match.

How much does tirzepatide cost at PlexusDx?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan), with flat pricing across all doses—your dose may increase, but your monthly cost remains the same. Treatment is available nationwide without insurance, and HSA/FSA accounts are accepted.

What side effects should I expect from tirzepatide?

Most common side effects include nausea, vomiting, and constipation, which typically diminish as your body adjusts over 4-8 weeks. Serious side effects are rare but may include pancreatitis or thyroid concerns; PlexusDx reviews medical history during consultation to ensure safe candidacy for treatment.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes—PlexusDx Precision Peptide Genetic Test identifies variants in GIPR and FTO, and MC4R genes that influence your metabolic response to tirzepatide and other peptide therapies. This $298 test maps 14 pathways and 150+ genetic insights to personalize your treatment plan before starting medication.

Related Reading

• Zepbound For Losing Weight
• Wegovy Vs Zepbound Weight Loss
• Zepbound For Weight Loss
• Maxlife Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.